{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:36:00Z","timestamp":1769765760883,"version":"3.49.0"},"reference-count":40,"publisher":"Akademiai Kiado Zrt.","issue":"33","license":[{"start":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T00:00:00Z","timestamp":1692489600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,8,20]]},"abstract":"<jats:p>Napjainkban a nem alkoholos zs\u00edrm\u00e1jbetegs\u00e9g a leggyakoribb id\u00fclt m\u00e1jbetegs\u00e9g,\n                    ennek ellen\u00e9re nincs egy\u00e9rtelm\u0171en elfogadott, hat\u00e9kony ter\u00e1pi\u00e1ja. Az bizonyos,\n                    hogy a betegs\u00e9gben szenved\u0151k sz\u00e1ma egyre n\u00f6vekszik, emiatt a megel\u0151z\u00e9s, a\n                    kezel\u00e9s \u00e9s a t\u00e1rsbetegs\u00e9gek felismer\u00e9se kiemelten fontos. A jelenlegi evidencia\n                    szerint a nem alkoholos zs\u00edrm\u00e1jbetegs\u00e9g kialakul\u00e1s\u00e1nak h\u00e1tter\u00e9ben k\u00fcl\u00f6nb\u00f6z\u0151\n                    eredet\u0171, k\u00f3roki t\u00e9nyez\u0151k \u00e1llhatnak. A f\u0151 k\u00f3rokok k\u00f6z\u00f6tt a genetikai faktorok,\n                    tov\u00e1bb\u00e1 a szerzett k\u00f6rnyezeti hat\u00e1sok, valamint az \u00e9letm\u00f3d szerepelnek.\n                    \u00c9letm\u00f3d-v\u00e1ltoztat\u00e1ssal, azaz az \u00e1rt\u00f3 t\u00e9nyez\u0151k kik\u00fcsz\u00f6b\u00f6l\u00e9s\u00e9vel, cs\u00f6kkent\u00e9s\u00e9vel\n                    ak\u00e1r visszaford\u00edthat\u00f3 is lehet a m\u00e1jk\u00e1rosod\u00e1s a betegs\u00e9g st\u00e1dium\u00e1t\u00f3l f\u00fcgg\u0151en.\n                    Ebben az \u00f6sszefoglal\u00f3 k\u00f6zlem\u00e9nyben r\u00f6viden \u00e1ttekintj\u00fck a betegs\u00e9g\n                    patofiziol\u00f3gi\u00e1j\u00e1t, a kock\u00e1zati t\u00e9nyez\u0151ket, valamint a ter\u00e1pi\u00e1s lehet\u0151s\u00e9geket,\n                    azon bel\u00fcl els\u0151sorban az \u00e9letm\u00f3d-v\u00e1ltoztat\u00e1st (az \u00e9trendi v\u00e1ltoztat\u00e1sokat, a\n                    fizikai aktivit\u00e1s n\u00f6vel\u00e9s\u00e9t \u00e9s a tests\u00falycs\u00f6kken\u00e9st). Tov\u00e1bb\u00e1 az \u00f3mega-3\n                    zs\u00edrsavak \u2013 mint az eikozapenta\u00e9nsav \u00e9s a dokozahexa\u00e9nsav \u2013 jelent\u0151s\u00e9g\u00e9t is\n                    r\u00e9szletesen bemutatjuk. Ismereteink b\u0151v\u00fcl\u00e9se a j\u00f6v\u0151ben a nem alkoholos\n                    zs\u00edrm\u00e1jbetegs\u00e9g egy\u00e9nre szabott kezel\u00e9s\u00e9nek kidolgoz\u00e1s\u00e1t seg\u00edtheti. Orv Hetil.\n                    2023; 164(33): 1294\u20131299.<\/jats:p>","DOI":"10.1556\/650.2023.32834","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T08:58:51Z","timestamp":1692608331000},"page":"1294-1299","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":2,"title":["Az \u00f3mega-3 zs\u00edrsavak jelent\u0151s\u00e9ge a nem alkoholos zs\u00edrm\u00e1jbetegs\u00e9g kezel\u00e9s\u00e9ben"],"prefix":"10.1556","volume":"164","author":[{"given":"Rebeka Anna","family":"Mak\u00f3","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Seb\u00e9szeti, Transzplant\u00e1ci\u00f3s \u00e9s Gasztroenterol\u00f3giai Klinika Budapest, \u00dcll\u0151i \u00fat 78., 1082 Magyarorsz\u00e1g"},{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, K\u00eds\u00e9rletes \u00e9s Seb\u00e9szeti M\u0171t\u00e9ttani Tansz\u00e9k Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Egresi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Seb\u00e9szeti, Transzplant\u00e1ci\u00f3s \u00e9s Gasztroenterol\u00f3giai Klinika Budapest, \u00dcll\u0151i \u00fat 78., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bl\u00e1zovics","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, K\u00eds\u00e9rletes \u00e9s Seb\u00e9szeti M\u0171t\u00e9ttani Tansz\u00e9k Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9ka","family":"Oszl\u00e1nyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, K\u00eds\u00e9rletes \u00e9s Seb\u00e9szeti M\u0171t\u00e9ttani Tansz\u00e9k Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Hagym\u00e1si","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Seb\u00e9szeti, Transzplant\u00e1ci\u00f3s \u00e9s Gasztroenterol\u00f3giai Klinika Budapest, \u00dcll\u0151i \u00fat 78., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice J","year":"2018","unstructured":"1 Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018; 18: 245-250.","journal-title":"Clin Med (Lond)"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/microorganisms9050957","article-title":"Pathogenetic mechanisms, microbiota signatures, and therapeutic interventions","volume":"9","author":"2 Hrncir","year":"2021","unstructured":"2 Hrncir T, Hrncirova L, Kverka M, et al. Gut microbiota and NAFLD. Pathogenetic mechanisms, microbiota signatures, and therapeutic interventions. Microorganisms 2021; 9: 957.","journal-title":"Microorganisms"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/cld.1027","article-title":"Epidemiology of pediatric nonalcoholic fatty liver disease","volume":"17","author":"EL","year":"2021","unstructured":"3 Yu EL, Schwimmer JB. Epidemiology of pediatric nonalcoholic fatty liver disease. Clin Liver Dis (Hoboken) 2021; 17: 196-199.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 P\u00e1r A, Wittmann I, P\u00e1r G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus. I. Pathogenesis. [A nem alkoholos zs\u00edrm\u00e1jbetegs\u00e9g \u00e9s a 2-es t\u00edpus\u00fa cukorbetegs\u00e9g. I. Patogenezis.] Orv Hetil. 2022; 163: 815-825. [Hungarian]","DOI":"10.1556\/650.2022.32479"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3748\/wjg.v25.i11.1307","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice","volume":"25","author":"5 Zhou","year":"2019","unstructured":"5 Zhou JH, Cai JJ, She ZG, et al. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol. 2019; 25: 1307-1326.","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 Heged\u00fcs V, Ger\u0151 D, Mih\u00e1ly Z, et al. Alimentary induced fatty liver and adjuvant therapy with effective natural bioactive molecules. [Aliment\u00e1ris eredet\u0171 k\u00eds\u00e9rletes zs\u00edrm\u00e1j \u00e9s adjuv\u00e1ns kezel\u00e9se term\u00e9szetes eredet\u0171 bioakt\u00edv hat\u00f3anyagokkal.] Orv Hetil. 2011; 152: 1035-1042. [Hungarian]","DOI":"10.1556\/OH.2011.29151"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"7 Pouwels","year":"2022","unstructured":"7 Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22: 63.","journal-title":"BMC Endocr Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/jcm11040968","article-title":"Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes","volume":"11","author":"8 Mantovani","year":"2022","unstructured":"8 Mantovani A, Dalbeni A, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. J Clin Med. 2022; 11: 968.","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili K","year":"2021","unstructured":"9 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab. 2021; 50: 101122.","journal-title":"Mol Metab"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10 Halmos T, Suba I. Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases. [A nem alkoholos zs\u00edrm\u00e1j mint a metabolikus szindr\u00f3ma komponense \u00e9s kauz\u00e1lis kapcsolatai egy\u00e9b k\u00f3rk\u00e9pekkel.] Orv Hetil. 2017; 158: 2051-2061. [Hungarian]","DOI":"10.1556\/650.2017.30936"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"11 Buzzetti","year":"2016","unstructured":"11 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048.","journal-title":"Metabolism"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3904\/kjim.2017.343","article-title":"Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity","volume":"33","author":"Kwak MS","year":"2018","unstructured":"12 Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med. 2018; 33: 64-74.","journal-title":"Korean J Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: facts and figures","volume":"1","author":"Hallsworth K","year":"2019","unstructured":"13 Hallsworth K, Adams LA. Lifestyle modification in NAFLD\/NASH: facts and figures. JHEP Rep. 2019; 1: 468-479.","journal-title":"JHEP Rep"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14 Egresi A, Lengyel G, Somogyi A, et al. Various pathways leading to the progression of chronic liver diseases. [Az id\u00fclt m\u00e1jbetegs\u00e9gek progresszi\u00f3j\u00e1hoz vezet\u0151 folyamatok.] Orv Hetil. 2016; 157: 290-297. [Hungarian]","DOI":"10.1556\/650.2015.30377"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"9233650","DOI":"10.1155\/2022\/9233650","article-title":"A Molecular insight into the role of antioxidants in nonalcoholic fatty liver diseases","volume":"2022","author":"Ezhilarasan D","year":"2022","unstructured":"15 Ezhilarasan D, Lakshmi T. A Molecular insight into the role of antioxidants in nonalcoholic fatty liver diseases. Oxid Med Cell Longev. 2022; 2022: 9233650.","journal-title":"Oxid Med Cell Longev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"716783","DOI":"10.3389\/fnut.2021.716783","article-title":"A systematic review and meta-analysis","volume":"8","author":"16 Houttu","year":"2021","unstructured":"16 Houttu V, Csader S, Nieuwdorp M, et al. Dietary interventions in patients with non-alcoholic fatty liver disease. A systematic review and meta-analysis. Front Nutr. 2021; 8: 716783.","journal-title":"Front Nutr"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Werling K, Lang\u00f3 A. Effects of physical activity in nonalcoholic fatty liver disease. [A fizikai aktivit\u00e1s hat\u00e1sa a nem alkoholos eredet\u0171 zs\u00edrm\u00e1jra.] Orv Hetil. 2020; 161: 203-207. [Hungarian]","DOI":"10.1556\/650.2020.31656"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10620-021-07018-x","article-title":"Time to step it up: mobile health intervention for lifestyle modification in patients with nonalcoholic fatty liver disease","volume":"67","author":"Faust A","year":"2022","unstructured":"18 Faust A, Stine JG. Time to step it up: mobile health intervention for lifestyle modification in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2022; 67: 403-405.","journal-title":"Dig Dis Sci"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19 P\u00e1r A, Hegyi JP, V\u00e1ncsa Sz, et al. Sarcopenia - 2021. Pathophysiology, diagnosis, therapy. [Sarcopenia - 2021. Patofiziol\u00f3gia, diagn\u00f3zis, ter\u00e1pia.] Orv Hetil. 2021; 162: 3-12. [Hungarian]","DOI":"10.1556\/650.2021.32015"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 Hagym\u00e1si K, Lengyel G. Non-alcoholic steatosis\/steatohepatitis - 2010. [Nem alkoholos steatosis\/steatohepatitis - 2010.] Orv Hetil. 2010; 151: 1940-1945. [Hungarian]","DOI":"10.1556\/oh.2010.28989"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3390\/nu13051442","article-title":"Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development","volume":"13","author":"21 Vancells Lujan","year":"2021","unstructured":"21 Vancells Lujan P, Vi\u00f1as Esmel E, Sacanella Meseguer E. Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development. Nutrients 2021; 13: 1442.","journal-title":"Nutrients"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/MCO.0000000000000706","article-title":"Protein and amino acids in nonalcoholic fatty liver disease","volume":"24","author":"22 Tric\u00f2","year":"2021","unstructured":"22 Tric\u00f2 D, Biancalana E, Solini A. Protein and amino acids in nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2021; 24: 96-101.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/gutjnl-2017-315940","article-title":"Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an aging population: the Rotterdam Study","volume":"68","author":"23 Alferink","year":"2019","unstructured":"23 Alferink LJ, Kiefte-de Jong JC, Erler NS, et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an aging population: the Rotterdam Study. Gut 2019; 68: 1088-1098.","journal-title":"Gut"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.sjbs.2018.12.016","article-title":"Lifestyle interventions for non-alcoholic fatty liver disease","volume":"26","author":"24 Ahmed","year":"2019","unstructured":"24 Ahmed IA, Mikail MA, Mustafa MR, et al. Lifestyle interventions for non-alcoholic fatty liver disease. Saudi J Biol Sci. 2019; 26: 1519-1524.","journal-title":"Saudi J Biol Sci"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25 Spooner MH, Jump DB. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand? Curr Opin Clin Nutr Metab Care 2019; 22: 103-110.","DOI":"10.1097\/MCO.0000000000000539"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 Paton CM, Ntambi JM. Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab. 2009; 297: E28-E37.","DOI":"10.1152\/ajpendo.90897.2008"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tifs.2022.01.006","article-title":"Futuristic food fortification with a balanced ratio of dietary \u03c9-3\/\u03c9-6 omega fatty acids for the prevention of lifestyle diseases","volume":"120","author":"27 Alok","year":"2022","unstructured":"27 Alok P, Sneha SD, Varsha KM, et al. Futuristic food fortification with a balanced ratio of dietary \u03c9-3\/\u03c9-6 omega fatty acids for the prevention of lifestyle diseases. Trends Food Scie Tech. 2022; 120: 140-153.","journal-title":"Trends Food Scie Tech"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/nu11010046","article-title":"Omega-3 polyunsaturated fatty acids: benefits and endpoints in sport","volume":"11","author":"28 Gammone","year":"2018","unstructured":"28 Gammone MA, Riccioni G, Parrinello G, et al. Omega-3 polyunsaturated fatty acids: benefits and endpoints in sport. Nutrients 2018; 11: 46.","journal-title":"Nutrients"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mam.2018.03.001","article-title":"Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action","volume":"64","author":"Scorletti E","year":"2018","unstructured":"29 Scorletti E, Byrne CD. Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action. Mol Aspects Med. 2018; 64: 135-146.","journal-title":"Mol Aspects Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pbb.2013.06.001","article-title":"Influence of trans fat and omega-3 on the preference of psychostimulant drugs in the first generation of young rats","volume":"110","author":"30 Kuhn","year":"2013","unstructured":"30 Kuhn FT, Roversi K, Antoniazzi CT, et al. Influence of trans fat and omega-3 on the preference of psychostimulant drugs in the first generation of young rats. Pharmacol Biochem Behav. 2013; 110: 58-65.","journal-title":"Pharmacol Biochem Behav"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31 Varga Zs. Cardioprotective role of omega-3 polyunsaturated fatty acids. [Az omega-3 t\u00f6bbsz\u00f6r\u00f6sen tel\u00edtetlen zs\u00edrsavak az atherosclerosis megel\u0151z\u00e9s\u00e9ben.] Orv Hetil. 2008; 149: 627-637. [Hungarian]","DOI":"10.1556\/OH.2008.28296"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1476-511X-8-54","article-title":"Cytotoxicity of unsaturated fatty acids in fresh human tumor explants: concentration thresholds and implications for clinical efficacy","volume":"8","author":"Scheim","year":"2009","unstructured":"32 Scheim, DE. Cytotoxicity of unsaturated fatty acids in fresh human tumor explants: concentration thresholds and implications for clinical efficacy. Lipids Health Dis. 2009; 8: 54.","journal-title":"Lipids Health Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.3390\/ijms21144965","article-title":"EPA and DHA fatty acids induce a remodeling of tumor vasculature and potentiate docetaxel activity","volume":"21","author":"33 Goupille","year":"2020","unstructured":"33 Goupille C, Vibet S, Frank PG, et al. EPA and DHA fatty acids induce a remodeling of tumor vasculature and potentiate docetaxel activity. Int J Mol Sci. 2020; 21: 4965.","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.3390\/ijms20194851","article-title":"Omega fatty acids and inflammatory bowel diseases: an overview","volume":"20","author":"34 Marton","year":"2019","unstructured":"34 Marton LT, Goulart RA, Carvalho AC, et al. Omega fatty acids and inflammatory bowel diseases: an overview. Int J Mol Sci. 2019; 20: 4851.","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35 Fekete M, Sz\u0151ll\u0151si G, N\u00e9meth AN, et al. Clinical value of omega-3 polyunsaturated fatty acid supplementation in chronic obstructive pulmonary disease. [Az \u00f3mega-3 zs\u00edrsavak p\u00f3tl\u00e1s\u00e1nak klinikai \u00e9rt\u00e9ke kr\u00f3nikus obstrukt\u00edv t\u00fcd\u0151betegs\u00e9gben.] Orv Hetil. 2021; 162: 23-30. [Hungarian]","DOI":"10.1556\/650.2021.31973"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/ijms19020532","article-title":"The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiometabolic risk factors: a systematic review","volume":"19","author":"Innes JK","year":"2018","unstructured":"36 Innes JK, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiometabolic risk factors: a systematic review. Int J Mol Sci. 2018; 19: 532.","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/ijo.2016.27","article-title":"Omega-3 fatty acids prevent early-life antibiotic exposure-induced gut microbiota dysbiosis and later-life obesity","volume":"40","author":"37 Kaliannan","year":"2016","unstructured":"37 Kaliannan K, Wang B, Li XY, et al. Omega-3 fatty acids prevent early-life antibiotic exposure-induced gut microbiota dysbiosis and later-life obesity. Int J Obes (Lond). 2016; 40: 1039-1042.","journal-title":"Int J Obes (Lond)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pharmthera.2017.07.007","article-title":"Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease","volume":"181","author":"38 Jump","year":"2018","unstructured":"38 Jump DB, Lytle KA, Depner CM, et al. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther. 2018; 181: 108-125.","journal-title":"Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/ijms21030741","article-title":"Omega-3 versus omega-6 polyunsaturated fatty acids in the prevention and treatment of inflammatory skin diseases","volume":"21","author":"39 Bali\u0107","year":"2020","unstructured":"39 Bali\u0107 A, Vla\u0161i\u0107 D, \u017du\u017eul K, et al. Omega-3 versus omega-6 polyunsaturated fatty acids in the prevention and treatment of inflammatory skin diseases. Int J Mol Sci. 2020; 21: 741.","journal-title":"Int J Mol Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-nutr-071812-161230","article-title":"Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease","volume":"33","author":"Scorletti E","year":"2013","unstructured":"40 Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013; 33: 231-248.","journal-title":"Annu Rev Nutr"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/33\/article-p1294.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/33\/article-p1294.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/33\/article-p1294.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:36:41Z","timestamp":1697801801000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/33\/article-p1294.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,20]]},"references-count":40,"journal-issue":{"issue":"33"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32834","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,20]]}}}